The reiteration of an 'Outperform' rating by Credit Suisse indicates their positive outlook on Jasper Therapeutics. The maintained price target of $4 suggests that they believe the stock is currently undervalued. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.